Risk score-guided dual antiplatelet therapy in Korean acute coronary syndrome patients receiving bioabsorbable-polymer everolimus eluting stent (Synergy stent)
Not Applicable
Recruiting
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0006003
- Lead Sponsor
- Chonnam National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Patients = 19 years old
-Patients with acute coronary syndrome having lesions requiring interventions amendable for implantation of Synergy during the index procedure
-Patients who voluntarily decide to participate in this research and agree to the consent form
Exclusion Criteria
-Female of childbearing potential, who possibly plans to become pregnant any time after enrollment into this study
- If the life expectancy is less than three years
-Patients requiring oral anticoagulation
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method et adverse clinical events defined as a composite of all-cause death, myocardial infarction, repeat percutaneous coronary intervention or coronary artery bypass graft surgery, stent thrombosis, stroke, and major/minor bleeding [BARC type 3-5/1-2]
- Secondary Outcome Measures
Name Time Method Major adverse cardiac and cerebrovascular events defined as a composite of all-cause death, myocardial infarction, repeat percutaneous coronary intervention or coronary artery bypass graft surgery, stent thrombosis, and stroke;All-cause death;Myocardial infarction;Repeat percutaneous coronary intervention or coronary artery bypass graft surgery;Stent thrombosis;Stroke;Major or minor bleeding [BARC type 3-5/1-2]